论文部分内容阅读
目的观察FOLFOX4方案治疗晚期食管癌的疗效及不良反应。方法按FOLFOX4方案,奥沙利铂85mg/m2,静脉滴注,第1d;CF200mg/m2,静脉滴注,第1,2d;5-FU400mg/m2静脉推注,5-FU600mg/m2持续泵入22h,第1,2d;每2周重复。结果可评价疗效者42例,总有效率52.4%,其中CR1例(2.4%),PR21例(50.0%),SD11例(26.2%),PD9例(21.4%),临床获益率78.6%。中位TTP5.6个月,1年生存率45.2%。不良反应较轻,无化疗相关死亡。结论 FOLFOX4方案治疗晚期食管癌临床疗效较好,不良反应可以耐受。
Objective To observe the efficacy and adverse reactions of FOLFOX4 regimen in the treatment of advanced esophageal cancer. Methods according to FOLFOX4 protocol, oxaliplatin 85mg/m2, intravenous drip, the first day; CF200mg/m2, intravenous drip, the first, 2d; 5-FU 400mg/m2 intravenous injection, 5-FU 600mg/m2 continuous pumping 22h, 1st, 2d; repeated every 2 weeks. Results The efficacy rate was 42. The total effective rate was 52.4%, including CR1 (2.4%), PR21 (50.0%), SD11 (26.2%), PD9 (21.4%), and clinical benefit rate 78.6%. The median TTP was 5.6 months and the 1 year survival rate was 45.2%. The adverse reactions were mild and there was no chemotherapy-related death. Conclusion The FOLFOX4 regimen has good clinical efficacy in the treatment of advanced esophageal cancer, and adverse reactions can be tolerated.